Incremental peritoneal dialysis is a safe and feasible prescription in incident patients with preserved residual kidney function. Issue 1 (21st August 2021)

• Record Type: Journal Article
• Authors: Huang, Louis L.; Mah, Jia Y.; Howard, Jennifer; Roberts, Matthew A.; McMahon, Lawrence P.
• Is Part Of: Nephrology. Volume 27:Issue 1(2022)
• Page Start: 74
• Page End: 81
• Publication Date: 2021-08-21
• Subjects: incremental dialysis -- peritonitis -- residual kidney function -- technique survival; Nephrology -- Periodicals; Kidneys -- Diseases -- Periodicals; Nephrologists -- Periodicals; 616.61; 616.61
• DOI: 10.1111/nep.13962
• Languages: English
• ISSNs: 1320-5358

Abstract

Abstract: Background: Incremental peritoneal dialysis (PD) is recommended as a component of high‐quality care by the international society for PD; however, its feasibility and clinical outcomes have not been widely reported. The aim of this study is to describe our experience with incremental PD. Methods: This was a retrospective cohort study of incident PD patients at Eastern Health between 2015 and 2019. Patients who stopped PD within 30 days were excluded. Incremental PD was defined in CAPD as using <8 L/day of exchange volume and in automated PD as dialysing without a last fill. Dialysis modality accorded with patient and physician preferences. Results: The 96 patients were included in this study; 54 with incremental PD. Compared to full‐dose PD, incremental PD patients were more likely to be female, had less comorbid diabetes (28% vs. 52%) and higher residual kidney function (RKF) (Kt/V 2.0 ± 0.7 vs. 1.4 ± 0.7). Age, BMI and starting eGFR did not differ between groups. Incremental PD exposed patients to lower exchange volumes (4.4 ± 2.1 vs. 8.5 ± 1.1 L/day), glucose load (46 ± 41 g/day vs. 119 ± 46) and was associated with a longer peritonitis‐free survival. PD technique survival, rates of peritonitis or hospitalization were comparable between groups. Predictors for longer incremental PD use included older age and higher starting eGFR. Conclusions: Incremental PD is a feasible, goal‐directed initial prescription in patients with RKF with comparable peritonitis rates and technique survival. Validation of this prescription in prospective studies is warranted. SUMMARY AT A GLANCE: The authors retrospectively compared patients on incremental PD with standard PD dose in ANZ, and found that those treated with an incremental strategy had a longer peritonitis‐free period and comparable rates of peritonitis, hospitalization and technique survival.